Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X about a recent paper published in BMT journal.

“Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT”

Authors: Razan Mohty et al.

“Check our newly published article on outcomes of patients with IDH1 or 2 mutated AML after alloHCT, a study of the ALWP of The EBMT in BMT journal.

Thank you Abdul-Hamid Bazarbachi, Mohamad Mohty, Myriam Labopin, and all co-authors.”

Source: Razan Mohty/X

More posts by Razan Mohty in OncoDaily.